Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li> Management's primary operational goal for 2025 is to secure multiple licensing agreements for human diagnostic applications.</li><li>In September Volition entered into two such licensing agreements The company's 1st commercial order for Nu.Q Cancer assays was received in November.</li><li> The key financial goal for 2025 is to achieve cash neutrality on a full-year basis.</li></ul>

 Management's primary operational goal for 2025 is to secure multiple licensing agreements for human diagnostic applications.In September Volition entered into two such licensing agreements The company's 1st commercial order for Nu.Q Cancer assays was received in November. The key financial goal for 2025 is to achieve cash neutrality on a full-year basis.

VNRX: 3Q 2025 results reported  Revenues & EPS above our expectations  cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025.

VolitionRX

VNRX: 3Q 2025 results reported Revenues & EPS above our expectations cost cutting very evident. At least seven major operational milestones have been achieved thus far in 2025.